$GILD

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - CoreWeave (NASDAQ:CRWV), CPS Technologies (NASDAQ:CPSH)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Original reporting
Benzinga · Avi Kapoor
Published Nov 13, 2025, 1:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 13, 2025, 2:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - CoreWeave (NASDAQ:CRWV), CPS Technologies (NASDAQ:CPSH) — source image
Decision brief

The 30-second read

$GILDBullishMed
01

Why it matters

The bullish coverage of GILD could lead to short-term price appreciation, especially if broader market conditions remain stable.

02

Market read

The news primarily affects the biotech and financial sectors, with GILD being the most impacted due to analyst coverage.

03

What to watch

Potential regulatory changes or sector-wide downturns could negatively impact these stocks despite analyst coverage.

Timing: Short to medium term (1-3 months)

Background

Recent analyst activities indicate a cautious optimism in the biotech sector, with GILD receiving a bullish initiation.

Company-level read

Ticker impact

$GILDBullishHigh confidence
Context

High relevance due to analyst initiation and bullish outlook.

Expected impact

Moderate increase of approximately 5-10% over the next 1-3 months.

Evidence & confidence

The analyst's bullish coverage, combined with GILD's recent performance and industry position, supports a positive outlook.

$CRWVNeutralMedium confidence
Context

Moderate relevance; analyst coverage suggests some market interest.

Expected impact

Minimal; expected price movement within 2% in the short term.

Evidence & confidence

The neutral stance suggests limited trading action; traders should monitor for further developments.

$CPSHNeutralMedium confidence
Context

Moderate relevance; analyst initiation with a neutral sentiment.

Expected impact

Expected price stability with fluctuations within 2%.

Evidence & confidence

Neutral analyst coverage indicates cautious market sentiment; traders should wait for clearer signals.

Market effects

Potential positive sentiment in biotech and life sciences sectors due to GILD's bullish coverage.

Limited; primarily US-focused news with minimal regional implications.

Moderate; GILD's global presence may influence international biotech markets.

Counterpoint

The analyst's bullish initiation on GILD may be overly optimistic; recent market volatility could temper gains.

Key entities

  • Gilead Sciences

    A leading biopharmaceutical company specializing in antiviral drugs.

  • CoreWeave

    A cloud computing and GPU infrastructure provider.

  • CPS Technologies

    A manufacturer of advanced materials and components.

  • Veeva Systems

    A cloud software provider for life sciences and other industries.

  • Bank of Nova Scotia

    A major Canadian bank with diverse financial services.

Related articles

$GILDMedAI 8/10

Once-weekly oral islatravir-lenacapavir is noninferior to daily HIV therapy

A phase 3 trial found that switching to once-weekly oral islatravir-lenacapavir (ISL/LEN) maintained HIV-1 suppression as effectively as daily bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF). The study met noninferiority criteria, with similar adverse event rates and no resistance to ISL/LEN. Gilead Sciences and Merck Sharp and Dohme funded the trial. The results apply only to those already virologically suppressed on B/F/TAF. Longer-term data is needed.

$NBISHighAI 8/10

Forget CoreWeave — This Is the AI Stock You Should Instead Be Buying

Nebius (NBIS) reported 454% revenue growth last quarter, with $8B cash and near-zero debt. It has contracts with Microsoft (MSFT) and Meta (META) potentially worth $19B and $27B, supported by a $4B NVIDIA (NVDA) stake. CoreWeave (CRWV) reported $2.575B Q2 revenue but widened net loss to $626M and high debt levels.

$CRWVMedAI 8/10

AI Infrastructure Stocks Surge: How Long Can CoreWeave (CRWV) and Super Micro Computer (SMCI) Keep It Up?

CoreWeave (CRWV) and Super Micro Computer (SMCI) shares surged to 3-month highs after both companies issued strong forecasts, signaling high demand for AI computing. CRWV raised revenue and profit forecasts, with a revenue backlog of $104.2B. SMCI exceeded revenue estimates and improved gross margins. Both companies benefit from AI infrastructure growth but face risks related to debt and market volatility.

$GILDHighAI 9/10

AIDS 2026: Long-Acting Weekly Oral HIV Therapy Advances Toward Regulatory Review

Gilead Sciences and Merck reported positive phase 3 trial results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. The ISLEND-1 and ISLEND-2 trials showed the regimen maintained virologic suppression comparable to daily treatments, with 0% and 0.3% of participants having HIV-1 RNA levels above 50 copies/mL, respectively. The companies plan to submit these findings for regulatory review.

$GILDHighAI 9/10

Gilead Sciences Expands Trodelvy's Role In First-Line Metastatic TNBC

Gilead Sciences (GILD) received European Commission approval for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for first-line metastatic triple-negative breast cancer (TNBC). The approval, based on Phase 3 study results, shows a 35% reduction in disease progression or death risk. Trodelvy is now established as a backbone therapy for TNBC across PD-L1 status. GILD stock closed at $146.12 on August 21, 2026, and is up 0.75% in pre-market trading.